β1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids

被引:195
作者
Casey, RC
Burleson, KM
Skubitz, KM
Pambuccian, SE
Oegema, TR
Ruff, LE
Skubitz, APN
机构
[1] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Dept Orthopaed Surg, Minneapolis, MN 55455 USA
关键词
D O I
10.1016/S0002-9440(10)63058-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Ovarian carcinoma multicellular spheroids are an in vitro model of micrometastasis whose adhesive abilities have not been elucidated. In this study, we identified adhesion molecules that mediate the formation of ovarian carcinoma spheroids and their subsequent adhesion to extracellular matrix proteins. The NIH; OVCAR5, but not the SKOV3, ovarian carcinoma cell fine formed spheroids similar to multicellular aggregates isolated from patient ascitic fluid. NIH:OVCAR5 spheroid formation was augmented by a beta1-integrin-stimulating monoclonal antibody or exogenous fibronectin, but was inhibited by blocking monoclonal antibodies against the alpha5- or beta1-integrin subunits. By immunohistochemical staining, alpha2-, alpha3-, alpha5-, alpha6-, and beta1-integrin subunits, CD44, and fibronectin were detected in NIH:OVCAR5 spheroids. NIH:OVCAR5 spheroids adhered to fibronectin, laminin, and type IV collagen, and this adhesion was partially inhibited by blocking antibodies against the alpha5-, alpha6-, and alpha2-integrin subunits, respectively. A blocking monoclonal antibody against the beta1-integrin subunit completely inhibited adhesion of the spheroids to all three proteins. These results suggest that interactions between the alpha5 beta1-integrin and fibronectin mediate the formation of ovarian carcinoma spheroids and that their adhesion to extracellular matrix proteins at sites of secondary tumor growth may be mediated by a complex interaction between multiple integrins; and their ligands.
引用
收藏
页码:2071 / 2080
页数:10
相关论文
共 45 条
  • [1] A defect in cell-to-cell adhesion via integrin-fibronectin interactions in a highly metastatic tumor cell line
    Abe, Y
    Tsutsui, T
    Mu, J
    Kosugi, A
    Yagita, H
    Sobue, K
    Niwa, O
    Fujiwara, H
    Hamaoka, T
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1997, 88 (01): : 64 - 71
  • [2] ALLEN HJ, 1987, EXP CELL BIOL, V55, P194
  • [3] CD44 IS THE PRINCIPAL CELL-SURFACE RECEPTOR FOR HYALURONATE
    ARUFFO, A
    STAMENKOVIC, I
    MELNICK, M
    UNDERHILL, CB
    SEED, B
    [J]. CELL, 1990, 61 (07) : 1303 - 1313
  • [4] USE OF MULTICELL SPHEROIDS OF OVARIAN-CARCINOMA AS AN INTRAPERITONEAL RADIO-IMMUNOTHERAPY MODEL - UPTAKE, RETENTION KINETICS AND DOSIMETRIC EVALUATION
    BARDIES, M
    THEDREZ, P
    GESTIN, JF
    MARCILLE, BM
    GUERREAU, D
    FAIVRECHAUVET, A
    MAHE, M
    SAIMAUREL, C
    CHATAL, JF
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (06) : 984 - 991
  • [5] 3-DIMENSIONAL GROWTH AND DIFFERENTIATION OF OVARIAN TUMOR-CELL LINE IN HIGH ASPECT ROTATING-WALL VESSEL - MORPHOLOGIC AND EMBRYOLOGIC CONSIDERATIONS
    BECKER, JL
    PREWETT, TL
    SPAULDING, GF
    GOODWIN, TJ
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, 51 (03) : 283 - 289
  • [6] Extracellular matrix signaling: integration of form and function in normal and malignant cells
    Boudreau, N
    Bissell, MJ
    [J]. CURRENT OPINION IN CELL BIOLOGY, 1998, 10 (05) : 640 - 646
  • [7] Integrin-mediated adhesion and signalling in ovarian cancer cells
    Buczek-Thomas, JA
    Chen, N
    Hasan, T
    [J]. CELLULAR SIGNALLING, 1998, 10 (01) : 55 - 63
  • [8] CD44 VARIANT EXPRESSION IS A COMMON FEATURE OF EPITHELIAL OVARIAN-CANCER - LACK OF ASSOCIATION WITH STANDARD PROGNOSTIC FACTORS
    CANNISTRA, SA
    ABUJAWDEH, G
    NILOFF, J
    STROBEL, T
    SWANSON, L
    ANDERSEN, J
    OTTENSMEIER, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) : 1912 - 1921
  • [9] EXPRESSION AND FUNCTION OF BETA-1 AND ALPHA-V-BETA-3 INTEGRINS IN OVARIAN-CANCER
    CANNISTRA, SA
    OTTENSMEIER, C
    NILOFF, J
    ORTA, B
    DICARLO, J
    [J]. GYNECOLOGIC ONCOLOGY, 1995, 58 (02) : 216 - 225
  • [10] Carreiras F, 1999, INT J CANCER, V80, P285